HealthEquity, Inc. $HQY Stock Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its HealthEquity stake by 54.5% in the third quarter, bringing its holdings to 32,776 shares valued at approximately $2.9 million. Institutional investors and hedge funds collectively own 99.55% of HQY.
• HealthEquity exceeded quarterly expectations, reporting $1.24 in earnings per share versus the $1.19 consensus estimate and $350.73 million in revenue. Revenue rose 95.5% year over year, while the company issued fiscal 2027 EPS guidance of $4.66–$4.73.
• Analysts maintain a positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $113.53, above the reported share price of $97.88. However, director Adrian Dillon sold 7,632 shares under a pre-arranged trading plan.

Assenagon Asset Management S.A. lifted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 54.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,776 shares of the company's stock after acquiring an additional 11,561 shares during the quarter. Assenagon Asset Management S.A.'s holdings in HealthEquity were worth $2,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in HealthEquity during the 2nd quarter valued at approximately $1,018,621,000. Wasatch Advisors LP increased its position in shares of HealthEquity by 10.5% during the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company's stock worth $719,014,000 after buying an additional 757,801 shares during the period. William Blair Investment Management LLC acquired a new stake in shares of HealthEquity during the second quarter worth $160,158,000. Dimensional Fund Advisors LP raised its stake in HealthEquity by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,627,039 shares of the company's stock worth $135,957,000 after buying an additional 45,287 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in HealthEquity during the second quarter worth $103,573,000. 99.55% of the stock is owned by institutional investors and hedge funds.

HealthEquity Stock Up 1.3%

Shares of NASDAQ HQY opened at $97.88 on Thursday. The firm has a market cap of $8.10 billion, a PE ratio of 35.34, a P/E/G ratio of 1.53 and a beta of 0.24. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The company's fifty day simple moving average is $95.47 and its 200 day simple moving average is $91.72. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.47.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.05. The business had revenue of $350.73 million during the quarter, compared to analysts' expectations of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm's revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, sell-side analysts forecast that HealthEquity, Inc. will post 3.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other HealthEquity news, Director Adrian Dillon sold 7,632 shares of the company's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total transaction of $798,383.52. Following the transaction, the director owned 62,395 shares in the company, valued at approximately $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.60% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on HQY shares. BTIG Research reaffirmed a "buy" rating and set a $115.00 price target on shares of HealthEquity in a research report on Friday, August 28th. Citigroup reissued a "market outperform" rating on shares of HealthEquity in a research report on Friday, August 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on HealthEquity from $135.00 to $142.00 and gave the company a "buy" rating in a research note on Monday, August 31st. BMO Capital Markets upped their target price on HealthEquity from $105.00 to $125.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, Raymond James Financial restated a "strong-buy" rating on shares of HealthEquity in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, HealthEquity currently has a consensus rating of "Moderate Buy" and an average price target of $113.53.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled benefits administration and financial services that help employers and individuals manage tax-advantaged healthcare accounts. The company's offerings include health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other consumer-directed benefits.

In addition to account administration, HealthEquity provides payment cards, investment options for eligible account holders, employee engagement tools, and digital platforms for managing healthcare benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.